Core Viewpoint - The company, New Mile Health Technology Group Co., Ltd., has achieved significant growth in revenue and profit in 2024, driven by strategic restructuring, resource integration, and technological innovation in the healthcare sector [1][3]. Group 1: Financial Performance - In 2024, the company reported a revenue of 3.799 billion yuan and a net profit attributable to shareholders of 115 million yuan, marking a substantial year-on-year increase of 296.13% [1]. Group 2: Healthcare Services Development - The company is addressing the uneven distribution of medical resources in China by expanding its healthcare services through strategic restructuring and scale expansion, focusing on regional medical needs [3]. - Key hospitals under the company, such as Siyang Hospital and Lankao First Hospital, are enhancing their specialized capabilities and optimizing their discipline layout to improve patient care [3]. - The company has successfully created a virtuous cycle of "scale expansion - quality improvement - efficiency growth" by enhancing operational efficiency and cost control, leading to increased market share and patient satisfaction [3]. Group 3: Pharmaceutical Manufacturing - With over 20 years in pharmaceutical manufacturing, the company has established a competitive advantage in the traditional Chinese medicine sector, centered around its core product, "Duyiwei Capsule" [3]. - The "Duyiwei Capsule" has been recognized for its unique efficacy, high safety, and low treatment costs, being included in the Chinese Pharmacopoeia and various national medical insurance directories [3]. Group 4: Marketing and Brand Development - The company has developed a dual-driven marketing model of "distribution + specialized academic promotion," investing in academic promotion for nearly a decade to build a stable sales team [4]. - The "Duyiwei" trademark was awarded "China Famous Trademark" in 2024, further solidifying its market position [4]. Group 5: Industry Trends and Future Outlook - The healthcare industry in China is experiencing favorable conditions due to an aging population and increasing chronic disease prevalence, with over 260 million chronic disease patients [4]. - The company plans to continue focusing on its dual main businesses of "healthcare + pharmaceuticals," enhancing regional medical center construction and increasing investment in innovative drug research and development [4].